PRME vs. TWST, DNLI, SWTX, ACLX, NVAX, APGE, ADMA, CGON, IOVA, and VCEL
Should you be buying Prime Medicine stock or one of its competitors? The main competitors of Prime Medicine include Twist Bioscience (TWST), Denali Therapeutics (DNLI), SpringWorks Therapeutics (SWTX), Arcellx (ACLX), Novavax (NVAX), Apogee Therapeutics (APGE), ADMA Biologics (ADMA), CG Oncology (CGON), Iovance Biotherapeutics (IOVA), and Vericel (VCEL). These companies are all part of the "biological products, except diagnostic" industry.
Twist Bioscience (NASDAQ:TWST) and Prime Medicine (NYSE:PRME) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, community ranking, media sentiment, earnings, dividends and risk.
Twist Bioscience has a beta of 1.78, meaning that its stock price is 78% more volatile than the S&P 500. Comparatively, Prime Medicine has a beta of 2.35, meaning that its stock price is 135% more volatile than the S&P 500.
Twist Bioscience currently has a consensus price target of $44.00, suggesting a potential downside of 12.73%. Prime Medicine has a consensus price target of $15.09, suggesting a potential upside of 129.69%. Given Twist Bioscience's higher possible upside, analysts clearly believe Prime Medicine is more favorable than Twist Bioscience.
Prime Medicine has lower revenue, but higher earnings than Twist Bioscience. Twist Bioscience is trading at a lower price-to-earnings ratio than Prime Medicine, indicating that it is currently the more affordable of the two stocks.
70.4% of Prime Medicine shares are owned by institutional investors. 3.9% of Twist Bioscience shares are owned by company insiders. Comparatively, 24.3% of Prime Medicine shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Twist Bioscience received 77 more outperform votes than Prime Medicine when rated by MarketBeat users. However, 72.22% of users gave Prime Medicine an outperform vote while only 56.96% of users gave Twist Bioscience an outperform vote.
Prime Medicine has a net margin of 0.00% compared to Prime Medicine's net margin of -69.24%. Prime Medicine's return on equity of -31.61% beat Twist Bioscience's return on equity.
In the previous week, Twist Bioscience had 5 more articles in the media than Prime Medicine. MarketBeat recorded 11 mentions for Twist Bioscience and 6 mentions for Prime Medicine. Twist Bioscience's average media sentiment score of 1.26 beat Prime Medicine's score of 0.67 indicating that Prime Medicine is being referred to more favorably in the news media.
Summary
Prime Medicine beats Twist Bioscience on 11 of the 17 factors compared between the two stocks.
Get Prime Medicine News Delivered to You Automatically
Sign up to receive the latest news and ratings for PRME and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PRME and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Prime Medicine Competitors List
Related Companies and Tools
